TY - JOUR
T1 - Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population
AU - SAPRIS-SERO Study Group
AU - Carrat, Fabrice
AU - Villarroel, Paola Mariela Saba
AU - Lapidus, Nathanael
AU - Fourié, Toscane
AU - Blanché, Hélène
AU - Dorival, Céline
AU - Nicol, Jérôme
AU - Deleuze, Jean François
AU - Robineau, Olivier
AU - Carrat, Fabrice
AU - Zins, Marie
AU - Severi, Gianluca
AU - Touvier, Mathilde
AU - Blanché, Hélène
AU - Deleuze, Jean François
AU - de Lamballerie, Xavier
AU - Lusivika-Nzinga, Clovis
AU - Pannetier, Gregory
AU - Lapidus, Nathanael
AU - Goderel, Isabelle
AU - Dorival, Céline
AU - Nicol, Jérôme
AU - Robineau, Olivier
AU - Kab, Sofiane
AU - Renuy, Adeline
AU - Le-Got, Stéphane
AU - Ribet, Céline
AU - Pellicer, Mireille
AU - Wiernik, Emmanuel
AU - Goldberg, Marcel
AU - Artaud, Fanny
AU - Gerbouin-Rérolle, Pascale
AU - Enguix, Mélody
AU - Laplanche, Camille
AU - Gomes-Rima, Roselyn
AU - Hoang, Lyan
AU - Correia, Emmanuelle
AU - Barry, Alpha Amadou
AU - Senina, Nadège
AU - Allegre, Julien
AU - de Edelenyi, Fabien Szabo
AU - Druesne-Pecollo, Nathalie
AU - Esseddik, Younes
AU - Hercberg, Serge
AU - Deschasaux, Mélanie
AU - Blanché, Hélène
AU - Sébaoun, Jean Marc
AU - Beaudoin, Jean Christophe
AU - Gressin, Laetitia
AU - Morel, Valérie
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Assessment of the intensity, dynamics and determinants of the antibody response after SARS-CoV-2 infection or vaccination in the general population is critical to guide vaccination policies. This study characterized the anti-spike IgG titers in 13,971 participants included in a French multicohort population-based serological survey on COVID-19 between April and October 2020 and followed-up with serological testing between May and October 2021. Eight follow-up profiles were defined depending on SARS-CoV-2 infection (0, 1 or 2) and COVID-19 vaccination (0, 1, 2 or 3). The anti-spike titer was lower in adults with no vaccination even in case of infection or reinfection, while it was higher in adults with infection followed by vaccination. The anti-spike titer was negatively correlated with age in vaccinated but uninfected adults, whereas it was positively correlated with age in unvaccinated but infected adults. In adults with 2 vaccine injections and no infection, the vaccine protocol, age, gender, and time since the last vaccine injection were independently associated with the anti-spike titer. The decrease in anti-spike titer was much more rapid in vaccinated than in infected subjects. These results highlight the strong heterogeneity of the antibody response against SARS-CoV-2 in the general population depending on previous infection and vaccination.
AB - Assessment of the intensity, dynamics and determinants of the antibody response after SARS-CoV-2 infection or vaccination in the general population is critical to guide vaccination policies. This study characterized the anti-spike IgG titers in 13,971 participants included in a French multicohort population-based serological survey on COVID-19 between April and October 2020 and followed-up with serological testing between May and October 2021. Eight follow-up profiles were defined depending on SARS-CoV-2 infection (0, 1 or 2) and COVID-19 vaccination (0, 1, 2 or 3). The anti-spike titer was lower in adults with no vaccination even in case of infection or reinfection, while it was higher in adults with infection followed by vaccination. The anti-spike titer was negatively correlated with age in vaccinated but uninfected adults, whereas it was positively correlated with age in unvaccinated but infected adults. In adults with 2 vaccine injections and no infection, the vaccine protocol, age, gender, and time since the last vaccine injection were independently associated with the anti-spike titer. The decrease in anti-spike titer was much more rapid in vaccinated than in infected subjects. These results highlight the strong heterogeneity of the antibody response against SARS-CoV-2 in the general population depending on previous infection and vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85130861755&partnerID=8YFLogxK
U2 - 10.1038/s41598-022-11787-4
DO - 10.1038/s41598-022-11787-4
M3 - Article
C2 - 35597776
AN - SCOPUS:85130861755
SN - 2045-2322
VL - 12
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 8622
ER -